We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

480 hedge funds and large institutions have $6.97B invested in Jazz Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 183 increasing their positions, 160 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more funds holding in top 10

Funds holding in top 10: 6 → 7 (+1)

14% more repeat investments, than reductions

Existing positions increased: 183 | Existing positions reduced: 160

0.86% more ownership

Funds ownership: 92% → 92.86% (+0.86%)

2% less capital invested

Capital invested by funds: $7.12B → $6.97B (-$152M)

4% less funds holding

Funds holding: 499 → 480 (-19)

18% less call options, than puts

Call options by funds: $19.5M | Put options by funds: $23.9M

21% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 68

Holders
480
Holders Change
-19
Holders Change %
-3.81%
% of All Funds
6.91%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.1%
New
54
Increased
183
Reduced
160
Closed
68
Calls
$19.5M
Puts
$23.9M
Net Calls
-$4.39M
Net Calls Change
-$11.9M

Top Buyers

1
Capital World Investors
Capital World Investors
California
+$175M
2
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
+$133M
3
CCM
Camber Capital Management
Massachusetts
+$58.2M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$53.9M
5
VPC
Vestal Point Capital
New York
+$45.9M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$128M
2
Swedbank
Swedbank
Sweden
-$127M
3
AC
Armistice Capital
New York
-$80.1M
4
Morgan Stanley
Morgan Stanley
New York
-$73.3M
5
Millennium Management
Millennium Management
New York
-$69.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$851M +$1.7M +13,888 +0.2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$777M +$10.4M +84,941 +1%
State Street
3
State Street
Massachusetts
$296M +$5.02M +41,010 +2%
LSV Asset Management
4
LSV Asset Management
Illinois
$287M +$4.61M +37,631 +2%
JP Morgan Chase
5
JP Morgan Chase
New York
$180M +$11.9M +97,254 +7%
PCM
6
Polaris Capital Management
Massachusetts
$173M +$20.2M +165,200 +13%
Capital World Investors
7
Capital World Investors
California
$172M +$175M +1,427,860 New
Ameriprise
8
Ameriprise
Minnesota
$165M +$6.88M +56,178 +4%
Pacer Advisors
9
Pacer Advisors
Pennsylvania
$156M +$33.1M +270,020 +26%
Renaissance Technologies
10
Renaissance Technologies
New York
$140M -$8.09M -66,006 -5%
CCM
11
Camber Capital Management
Massachusetts
$138M +$58.2M +475,000 +70%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$133M +$7.09M +57,922 +6%
VPC
13
Vestal Point Capital
New York
$132M +$45.9M +375,000 +52%
Fuller & Thaler Asset Management
14
Fuller & Thaler Asset Management
California
$131M +$133M +1,085,140 New
EC
15
EcoR1 Capital
California
$122M – – –
Fidelity Investments
16
Fidelity Investments
Massachusetts
$116M -$32.9M -268,612 -22%
Morgan Stanley
17
Morgan Stanley
New York
$115M -$73.3M -598,501 -38%
Franklin Resources
18
Franklin Resources
California
$113M +$7.36M +60,101 +7%
BG
19
Baupost Group
Massachusetts
$100M – – –
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$99.2M +$7.08M +57,803 +8%
AQR Capital Management
21
AQR Capital Management
Connecticut
$89.7M +$53.9M +440,363 +145%
APM
22
Avidity Partners Management
Texas
$70.3M +$11.6M +94,881 +19%
Bank of America
23
Bank of America
North Carolina
$68.4M +$11.9M +97,478 +21%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$67.5M -$2.36M -19,229 -3%
TSW
25
Thompson Siegel & Walmsley
Virginia
$66.5M +$24.5M +200,011 +57%
1
2 3 4 5

JAZZ Hedge Fund Activity: Q1 2024 in Review

480 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2024, worth a combined $6.97B — down 2.1% from $7.12B a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of JAZZ and 54 opened new positions — a net loss of 14 holders — while 160 trimmed existing stakes and 183 added.

The largest buyer was Capital World Investors, opening a new position worth an estimated $175M. The largest seller was Wellington Management Group, cutting an estimated $128M.

  • 480 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2024, down from 499 in Q4 2023.
  • Funds reported $6.97B of Jazz Pharmaceuticals stock for Q1 2024, down 2.1% quarter-over-quarter.
  • 54 funds opened new Jazz Pharmaceuticals positions in Q1 2024 and 68 closed out, a net change of -14 holders.
  • The largest Jazz Pharmaceuticals buyer in Q1 2024 was Capital World Investors, an estimated $175M added.
  • The largest Jazz Pharmaceuticals seller in Q1 2024 was Wellington Management Group, an estimated $128M sold.

Based on aggregated 13F filings for Q1 2024.